Millipore Sigma Vibrant Logo
Attention: We have moved. Merck Millipore products are no longer available for purchase on MerckMillipore.com.Learn More

OP43L Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1)

This Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) is validated for use in Frozen sections, Gel Shift, Immunoblotting, ICC, IP, Paraffin sections for the detection of p53 (Ab-6) (Pantropic).

Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) MSDS (material safety data sheet) or SDS, CoA and CoQ, dossiers, brochures and other available documents.
OP43L
Purchase on Sigma-Aldrich

概述

Replacement Information

重要规格表

Species ReactivityHostAntibody Type
Fe, HMMonoclonal Antibody

Products

产品目录编号包装 数量 / 包装
OP43L-100UGCN 塑胶安瓿;塑胶针药瓶 100 μg
Description
OverviewRecognizes the ~53 kDa wild-type and mutant p53 protein in A431 cells and breast carcinoma tissue.
Catalogue NumberOP43L
Brand Family Calbiochem®
References
ReferencesEl-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
Legros, Y., et al. 1994. Oncogene 9, 2071.
Barak, Y., et al. 1993. EMBO J. 12, 461.
Kastan, M.B., et al. 1992. Cell 71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
Lane, D.P. 1992. Nature 358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth. 151, 237.
Kastan, M.B., et al. 1991 Cancer Res. 51, 6304.
Product Information
FormLyophilized
FormulationLyophilized from a volatile buffer, 100 µg BSA.
Negative controlSK-OV-3 cells or normal skin tissue
Positive controlA431 cells or breast carcinoma tissue
PreservativeNone
Quality LevelMQ100
Applications
Application ReferencesImmunoprecipitation, Immunocytochemistry Loganzo, F., et al. 1994. Mol. Cell. Different. 2, 23. Paraffin Sections, Frozen Sections, Original Clone Vojtesek, B., et al. 1992. J. Immunol. Meth. 151, 237. Immunoblotting Loganzo, F., et al. 1994. Mol. Cell. Different. 2, 23. Epitope Legros, Y., et al. 1994. Oncogene 9, 2071.
Key Applications Frozen Sections
Gel Shift
Immunoblotting (Western Blotting)
Immunocytochemistry
Immunoprecipitation
Paraffin Sections
Application NotesFrozen sections (1 µg/ml; see application references)
Gel Shift (see comments)
Immunoblotting (0.1 µg/ml; see application references)
Immunocytochemistry (1-2.5 µg/ml; see application references)
Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
Application CommentsRecognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, resuspend in 100 µl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
Biological Information
Immunogenwild type, recombinant, human p53
ImmunogenHuman
EpitopeWithin amino acids 21-25 of human p53
CloneDO-1
HostMouse
IsotypeIgG2a
Species Reactivity
  • Feline
  • Human
Antibody TypeMonoclonal Antibody
Physicochemical Information
Dimensions
Materials Information
Toxicological Information
Safety Information according to GHS
Safety Information
Product Usage Statements
Storage and Shipping Information
Ship Code Ambient Temperature Only
Toxicity Standard Handling
Storage +2°C to +8°C
Do not freeze Ok to freeze
Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Reconstituted product will be more stable if 0.1% sodium azide is added (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least two hours. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage.
Packaging Information
Transport Information
Supplemental Information
Specifications
Global Trade Item Number
产品目录编号 GTIN
OP43L-100UGCN 04055977227536

Documentation

Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) MSDS

职位

物料安全数据表 (MSDS) 

Anti-p53 (Ab-6) (Pantropic) Mouse mAb (DO-1) 分析证书

标题批号
OP43L

参考

参考信息概述
El-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
Legros, Y., et al. 1994. Oncogene 9, 2071.
Barak, Y., et al. 1993. EMBO J. 12, 461.
Kastan, M.B., et al. 1992. Cell 71, 587.
Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
Lane, D.P. 1992. Nature 358, 15.
Vojtesek, B., et al. 1992. J. Immunol. Meth. 151, 237.
Kastan, M.B., et al. 1991 Cancer Res. 51, 6304.

小册子

标题
Caspases and other Apoptosis Related Tools Brochure

引用

标题
  • Frank Staib, et al. (2005) The p53 Tumor Suppressor Network is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress. Cancer Research 65, 10255-10264.
  • Hazel E. Warburton, et al. (2005) p53 regulation and function in renal cell carcinoma. Cancer Research 65, 6498-6503.
  • Urs Hobom and Matthias Dobbelstein. (2004) E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. Journal of Virology 78, 7685-7697.
    		•
    数据表

    Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

    Revision03-October-2007 RFH
    ApplicationFrozen sections (1 µg/ml; see application references)
    Gel Shift (see comments)
    Immunoblotting (0.1 µg/ml; see application references)
    Immunocytochemistry (1-2.5 µg/ml; see application references)
    Immunoprecipitation (1 µg/ml or use Cat. No. OP43A; see application references)
    Paraffin sections (1 µg/ml, pepsin, heat or pressure cooker pre-treatment required; see application references)
    DescriptionPurified mouse monoclonal antibody generated by immunizing BALB/c mice with the specified immunogen and fusing splenocytes with X63Ag8.653 mouse myeloma cells (see application references). Recognizes the ~53 kDa mutant and wild-type forms of p53.
    BackgroundThe human p53 tumor suppressor gene encodes a 393 amino acid phosphoprotein that exhibits sequence-specific DNA binding and directly interacts with various cellular and viral proteins. p53 is the most commonly mutated gene in human cancer, with the majority of the mutations being amino acid substitutions. The normal function of p53 is to effect cell cycle arrest at the G1 and G2 checkpoints in response to DNA damage. This checkpoint function is executed by accumulation of p53 followed by induction of the GADD45, WAF1, and MDM2 genes. The current model of p53 function postulates that p53 senses DNA damage and arrests the cell cycle in either the G1 or G2 phases to allow DNA repair to take place. If repair is not successful, p53 initiates programmed cell death.
    HostMouse
    Immunogen speciesHuman
    Immunogenwild type, recombinant, human p53
    EpitopeWithin amino acids 21-25 of human p53
    CloneDO-1
    IsotypeIgG2a
    Speciesfeline, human, not mouse, not rat
    Positive controlA431 cells or breast carcinoma tissue
    Negative controlSK-OV-3 cells or normal skin tissue
    FormLyophilized
    FormulationLyophilized from a volatile buffer, 100 µg BSA.
    PreservativeNone
    CommentsRecognizes both mutant and wild-type p53 under denaturing and non-denaturing conditions. This antibody reacts weakly with rodent p53; we do not recommend it for rodent samples. For gel shift assay, resuspend in 100 µl of buffer. Wild-type p53 has a short half life and is present in low amounts in cells. For immunoprecipitation increasing the amount of sample and labeling with 35S-Met for less than or equal to 1 h will aid in visualizing wild-type p53. Antibody should be titrated for optimal results in individual systems.
    Storage +2°C to +8°C
    Do Not Freeze Ok to freeze
    Special InstructionsWe recommend resuspending the lyophilized antibody with sterile phosphate buffered saline (PBS), pH 7.4, or sterile 20 mM Tris-saline (20 mM Tris containing 0.15 M NaCl), pH 7.4, to yield a final concentration of 100 μg/ml. Reconstituted product will be more stable if 0.1% sodium azide is added (do not add azide if antibody is to be used with viable cells). Lyophilized antibodies should be resuspended at 4°C with occasional gentle mixing for at least two hours. Following reconstitution, refrigerate (4°C) for short-term storage or aliquot and freeze (-20°C) for long-term storage.
    Toxicity Standard Handling
    ReferencesEl-Deiry, W.S., et al. 1994. Cancer Res. 54, 1169.
    Greenblatt, M.S., et al. 1994. Cancer Res. 54, 4855.
    Legros, Y., et al. 1994. Oncogene 9, 2071.
    Barak, Y., et al. 1993. EMBO J. 12, 461.
    Kastan, M.B., et al. 1992. Cell 71, 587.
    Kuerbitz, S.J. 1992. Proc. Natl. Acad. Sci. USA 89, 7491.
    Lane, D.P. 1992. Nature 358, 15.
    Vojtesek, B., et al. 1992. J. Immunol. Meth. 151, 237.
    Kastan, M.B., et al. 1991 Cancer Res. 51, 6304.
    Citation
  • Frank Staib, et al. (2005) The p53 Tumor Suppressor Network is a Key Responder to Microenvironmental Components of Chronic Inflammatory Stress. Cancer Research 65, 10255-10264.
  • Hazel E. Warburton, et al. (2005) p53 regulation and function in renal cell carcinoma. Cancer Research 65, 6498-6503.
  • Urs Hobom and Matthias Dobbelstein. (2004) E1B-55-kilodalton protein is not required to block p53-induced transcription during adenovirus infection. Journal of Virology 78, 7685-7697.
    		•
    Application referencesImmunoprecipitation, Immunocytochemistry Loganzo, F., et al. 1994. Mol. Cell. Different. 2, 23. Paraffin Sections, Frozen Sections, Original Clone Vojtesek, B., et al. 1992. J. Immunol. Meth. 151, 237. Immunoblotting Loganzo, F., et al. 1994. Mol. Cell. Different. 2, 23. Epitope Legros, Y., et al. 1994. Oncogene 9, 2071.